Latest news with #ClevelandClinicAbuDhabi
Al Etihad
2 days ago
- Business
- Al Etihad
Cleveland Clinic Abu Dhabi sets new standard in cardiovascular care with AlphaVac procedure
3 June 2025 13:51 ABU DHABI (ALETIHAD)Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully performed the AlphaVac thrombectomy, marking a significant milestone in advanced vascular AlphaVac device is a vacuum-assisted medical tool used to remove dangerous blood clots from the body, particularly large veins in the heart and minimally invasive, catheter-based technique helps reduce the risk of postoperative complications compared to traditional open-heart breakthrough procedure was performed by the hospital's Heart, Vascular & Thoracic Institute (HVTI) on a critically ill 70-year-old patient with multiple severe underlying health conditions, including hypertension, chronic kidney disease, heart failure, and atrial fibrillation (irregular heartbeats).The patient also had coronary artery disease and aortic valve stenosis, which is the narrowing of the heart's blood vessels and main valve, which had previously required her to undergo open-heart Georges-Pascal Haber, CEO of Cleveland Clinic Abu Dhabi, stated, 'As medical advancements rapidly accelerate, building a sustainable healthcare system requires a relentless commitment to innovation. Over the past decade, Cleveland Clinic Abu Dhabi has integrated cutting-edge technologies that improve patient outcomes and transform complex care delivery.'Dr. Houssam Younes, Department Chair, Vascular Surgery, Heart, Vascular & Thoracic Institute at Cleveland Clinic Abu Dhabi, said, "The AlphaVac offers a distinct minimally invasive advantage with its innovative nitinol basket and expandable funnel tip. It allows us to efficiently engage and remove large clot burdens with minimal blood loss."This case highlights the serious risks of lead infections and demonstrates how Cleveland Clinic Abu Dhabi is changing the landscape of high-risk cardiovascular care. Using the latest technology, the team safely removed the clot and the pacemaker, resolving the infection and ultimately helping the patient recover with minimal disruption. Source: Aletihad - Abu Dhabi
Al Etihad
28-05-2025
- Health
- Al Etihad
M42, Cleveland Clinic Abu Dhabi, Gunma University in Japan to drive innovation in heavy ion therapy for cancer treatment
28 May 2025 13:18 ABU DHABI (ALETIHAD)M42 and Cleveland Clinic Abu Dhabi, have signed a Memorandum of Cooperation (MoC) with Gunma University in Japan to accelerate research and innovation in heavy ion therapy, one of the most advanced and precise forms of radiation therapy for cancer collaboration, which took place during M42 and Cleveland Clinic Abu Dhabi's recent delegation visit to Japan, will see the three entities exchange knowledge, expertise, and research to deepen scientific understanding, and to broaden the clinical applications of heavy ion collaboration builds on M42 and Cleveland Clinic Abu Dhabi's recent partnership with Toshiba Energy Systems & Solutions Corporation (Toshiba ESS) to establish the region's first heavy ion therapy facility in Abu initiative will introduce one of the world's most innovative cancer treatment technologies to the Middle East, positioning Abu Dhabi as a centre of excellence in oncology and precision no heavy ion therapy centre within a five-hour flight of the UAE, the upcoming facility—strategically located on the Cleveland Clinic Abu Dhabi campus, adjacent to the Fatima bint Mubarak Centre, the region's first-of-its-kind comprehensive cancer centre—will enhance access to this treatment for patients across the Middle Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, said, "At Cleveland Clinic Abu Dhabi, our vision is to bring the most advanced, evidence-based treatments to our patients, and this partnership with Gunma University exemplifies that commitment. By combining our clinical expertise with Gunma's decades of leadership in heavy ion therapy, we are not only advancing scientific knowledge but also laying the groundwork for a new era of cancer care in the region."President Ishizaki Yasuki at Gunma University, commented, "Gunma University has long been committed to advancing the science of heavy ion therapy through rigorous research and clinical innovation."He added, "Partnering with M42 will enable us to expand the reach of this transformative therapy, fostering international collaboration and ensuring that more patients worldwide benefit from the latest advancements in cancer treatment." Gunma University has been at the forefront of radiation oncology and nuclear medicine in Japan for decades. The Gunma University Heavy Ion Medical Centre (GHMC), established in 2005, has been instrumental in refining heavy ion radiotherapy by integrating radiation biology, clinical studies, and cutting-edge treatment technologies. Source: Aletihad - Abu Dhabi
Al Bawaba
17-04-2025
- Health
- Al Bawaba
Cleveland Clinic Abu Dhabi collaborates with Cleveland Clinic in the U.S. to perform first-ever transcontinental robotic assisted focal therapy procedure for prostate cancer
Cleveland Clinic Abu Dhabi, part of the M42 group, has achieved a historic milestone in global healthcare. In collaboration with experts from Cleveland Clinic in the U.S., the team performed the world's first remotely conducted transcontinental robotic-assisted focal therapy for prostate cancer. Focal therapy is a non-invasive treatment that precisely targets a specific section of the prostate using ultrasound beams, eliminating the need for major surgery or radiation. The Focal-One system enhances this approach with a robotic arm that ensures precise and controlled ultrasound innovative surgery enabled real-time collaboration between Dr. Ruben Olivares, Urologist in the Glickman Urological Institute at Cleveland Clinic, supporting remotely from Ohio, and Dr. Waleed A. Hassen, Department Chair of Urology, at Cleveland Clinic Abu Dhabi, who managed the on-site procedural execution. Lasting approximately one hour, the remote procedure was completed successfully without complications, demonstrating the transformative potential of advanced technology in expanding access to specialized procedure, powered by cutting-edge technology and robust communication networks, offers unparalleled access to specialized surgical expertise, even in remote or underserved regions. By combining local and global expertise, it addresses critical gaps in healthcare equity and training while enabling minimally invasive treatment options, such as focal therapy for prostate cancer. However, widespread access to such advanced procedures remains a significant challenge in many parts of the on the milestone, Hasan Jasem Al Nowais, Chairman of Cleveland Clinic Abu Dhabi, said: 'This innovative remote procedure is a remarkable feat that presents the possibility to manage complex care needs across borders and close global health inequities. We were delighted to have partnered with our colleagues in the U.S. to set a new standard for transcontinental healthcare.' H.E. Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi (DoH), said: "Abu Dhabi is rapidly evolving towards establishing one of the world's most intelligent and efficient healthcare systems. Our progress is powered by advanced infrastructure and innovation-driven regulatory frameworks, which enhance healthcare quality and accessibility. Cleveland Clinic Abu Dhabi's achievements mark another milestone in our journey of healthcare excellence, showcasing the sector's commitment to pioneering medical solutions and cutting-edge technologies. This success strengthens our local and global partnerships, reaffirming the Emirate's dedication to safeguarding the health and well-being of our community and beyond." Highlighting the hospital's leadership in medical innovations, Dr. Georges-Pascal Haber, CEO of Cleveland Clinic Abu Dhabi said: 'Cleveland Clinic Abu Dhabi has always been at the forefront of integrating advanced technology with world-class care. Remote procedures represent the future of healthcare, pushing the boundaries of what can be achieved in medicine. This procedure exemplifies our vision of leveraging cutting-edge technology with collaborative expertise to set new benchmarks in patient care. It is exciting to partner with our colleagues in the US to make history and transform patient outcomes on a global scale. The success of this procedure marks a new era in global surgical collaboration. We envision a future where advanced treatments are accessible to patients regardless of location, reducing health disparities and improving outcomes for everyone.'The journey to this remarkable achievement began in October 2023, when Cleveland Clinic Abu Dhabi introduced the Focal One high-intensity focused ultrasound (HIFU) therapy to patients in Abu Dhabi. Focal One represents a novel approach to treating non-metastatic prostate tumors, utilizing advanced imaging technology to precisely target cancerous cells. This method enables effective tumor treatment while minimizing the risk of side Waleed A. Hassen, Department Chair of Urology at Cleveland Clinic Abu Dhabi, explains: "There are many ways to treat prostate cancer, and one of the options is focal therapy. It's a non-invasive procedure where we use a robotically controlled arm to deliver treatment. Once the treatment plan is in place, the machine delivers it precisely. This is proof of principle that we can contour the prostate, design the plan, and execute it remotely. The procedure typically takes about an hour, with the Focal-one screen visible to both the surgical team and the ultrasound team, ensuring shared expertise. Dr. Ruben Olivares, M.D., Urologist in the Glickman Urological Institute at Cleveland Clinic said: 'We are thrilled to have successfully performed the first-ever transcontinental robotic assisted focal therapy procedure for prostate cancer by working in tandem with our partners at Cleveland Clinic Abu Dhabi. Here at Cleveland Clinic, we use cutting-edge technology, but unfortunately, it's not available in many places throughout the U.S. and in the world. We look forward to expanding the adoption of the latest alternative minimally invasive options and increasing access for patients throughout the world with this first step." This milestone comes as Cleveland Clinic Abu Dhabi celebrates a decade of excellence in care, making remarkable strides in advancing healthcare through integration of technology. As the hospital continues to explore the potential of remote procedures, the implications stretch far beyond prostate cancer treatment. This success not only opens new pathways for surgical education and collaboration but also drives global accessibility to advanced care. © 2000 - 2025 Al Bawaba ( Signal PressWire is the world's largest independent Middle East PR distribution service.
Khaleej Times
16-04-2025
- Health
- Khaleej Times
UAE hospital performs transcontinental robotic-assisted focal therapy for prostate cancer
Cleveland Clinic Abu Dhabi, part of the M42 group, has achieved a historic milestone in global healthcare. In collaboration with experts from the Cleveland Clinic in the US, the team performed the world's first remotely conducted transcontinental robotic-assisted focal therapy for prostate cancer. Focal therapy is a non-invasive treatment that precisely targets a specific section of the prostate using ultrasound beams, eliminating the need for major surgery or radiation. The Focal-One system enhances this approach with a robotic arm that ensures precise and controlled ultrasound delivery. The innovative surgery enabled real-time collaboration between Dr. Ruben Olivares, Urologist in the Glickman Urological Institute at Cleveland Clinic, supporting remotely from Ohio, and Dr. Waleed A. Hassen, Department Chair of Urology, at Cleveland Clinic Abu Dhabi, who managed the on-site procedural execution. Lasting approximately one hour, the remote procedure was completed successfully without complications, demonstrating the transformative potential of advanced technology in expanding access to specialised care. Hasan Jasem Al Nowais, Chairman of Cleveland Clinic Abu Dhabi, said, 'This innovative remote procedure is a remarkable feat that presents the possibility to manage complex care needs across borders and close global health inequities. We were delighted to have partnered with our colleagues in the US to set a new standard for transcontinental healthcare.' Dr. Noura Al Ghaithi, Under-Secretary of the Department of Health – Abu Dhabi (DoH), said, "Abu Dhabi is rapidly evolving towards establishing one of the world's most intelligent and efficient healthcare systems. Our progress is powered by advanced infrastructure and innovation-driven regulatory frameworks, which enhance healthcare quality and accessibility. Cleveland Clinic Abu Dhabi's achievements mark another milestone in our journey of healthcare excellence, showcasing the sector's commitment to pioneering medical solutions and cutting-edge technologies. This success strengthens our local and global partnerships, reaffirming the Emirate's dedication to safeguarding the health and well-being of our community and beyond." Highlighting the hospital's leadership in medical innovations, Dr. Georges-Pascal Haber, CEO of Cleveland Clinic Abu Dhabi said: 'Cleveland Clinic Abu Dhabi has always been at the forefront of integrating advanced technology with world-class care. Remote procedures represent the future of healthcare, pushing the boundaries of what can be achieved in medicine. This procedure exemplifies our vision of leveraging cutting-edge technology with collaborative expertise to set new benchmarks in patient care. It is exciting to partner with our colleagues in the US to make history and transform patient outcomes on a global scale. The success of this procedure marks a new era in global surgical collaboration. We envision a future where advanced treatments are accessible to patients regardless of location, reducing health disparities and improving outcomes for everyone.' HIFU therapy The journey to this remarkable achievement began in October 2023, when Cleveland Clinic Abu Dhabi introduced the Focal One high-intensity focused ultrasound (HIFU) therapy to patients in Abu Dhabi. Focal One represents a novel approach to treating non-metastatic prostate tumours, utilising advanced imaging technology to precisely target cancerous cells. This method enables effective tumour treatment while minimising the risk of side effects. This milestone comes as Cleveland Clinic Abu Dhabi celebrates a decade of excellence in care, making remarkable strides in advancing healthcare through integration of technology. As the hospital continues to explore the potential of remote procedures, the implications stretch far beyond prostate cancer treatment. This success not only opens new pathways for surgical education and collaboration but also drives global accessibility to advanced care.
Arabian Business
16-04-2025
- Health
- Arabian Business
M42, Toshiba partner for groundbreaking cancer treatment facility in Abu Dhabi
M42, a global health champion powered by AI and technology, said its group company Cleveland Clinic Abu Dhabi is set to build the region's first heavy-ion therapy facility in Abu Dhabi, a move seen as giving hope to cancer sufferers in the region. Construction of the new facility will begin in 2026 at Cleveland Clinic Abu Dhabi's campus, adjacent to the recently launched Fatima bint Mubarak Center, a first-of-its-kind cancer center that delivers a multidisciplinary approach to cancer care, the company said. Next-gen cancer therapy The heavy-ion therapy system, which includes a treatment room equipped with a rotating gantry and another horizontally fixed beam treatment room, incorporates cutting-edge high-speed scanning irradiation technology and a compact rotating gantry equipped with superconducting magnets. Together with the Fatima bint Mubarak Center, this state-of-the-art facility further underscores Cleveland Clinic Abu Dhabi's position as a leader in oncology advancements and personalized care, offering a comprehensive and multidisciplinary approach to cancer treatment, under one roof, M42 said. View this post on Instagram A post shared by M42 Health (@m42health) The first heavy-ion therapy system in the region follows a strategic partnership between M42 and Toshiba Energy Systems & Solutions Corporation (Toshiba ESS). This collaboration will combine M42's expertise in healthcare innovation with Toshiba ESS's technological advancements in particle therapy, positioning Abu Dhabi as a hub for cutting-edge cancer treatment. The announcement on the new facility was made during Abu Dhabi Global Health Week (ADGHW) 2025, a major government initiative by the Department of Health – Abu Dhabi (DoH) that seeks to advance the future of health and well-being. With this new facility, M42 and Cleveland Clinic Abu Dhabi will be making history by bringing one of the most advanced and effective cancer treatment technologies to the Middle East, positioning Abu Dhabi as a global leader in oncology innovation and care. With no heavy-ion therapy center within a five-hour flight radius of the UAE, this facility ensures patients from across the region can access world-class care. This advanced form of radiation therapy will deliver unparalleled precision in targeting and destroying cancerous tumors with greater efficacy, revolutionizing cancer treatment and filling a critical gap in advanced care options for patients in the UAE and the broader region. With only 15 centers worldwide offering heavy-ion radiotherapy, the addition of this therapy to the Fatima bint Mubarak Center will position the region at the forefront of global oncology services.
